MRK241206P80000
- 0.05
- 0.000.00%
Merck & Co Newsroom
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
Incyte Gains Amid Takeover Speculation
Merck (MRK.US) / Kelun Biotech's ADC therapy has received breakthrough therapy designation from the FDA for the treatment of non-small cell lung cancer.
Previously, merck (MRK.US) reached a cooperation agreement with CStone Pharmaceuticals (06990), granting merck exclusive rights to develop, produce, and commercialize Sac-TMT outside the greater China region.
Electronic Arts, Lyft and 7 More Stocks That Can Benefit From Trump's R&D Policy
Express News | Merck & Co Inc : HSBC Raises to Buy From Hold
Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Nasdaq, S&P Ebb Near Record Highs, Dow Slips as JOLTS Report Kicks off Run of Jobs Data
Express News | Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Merck & Co., Inc.'s (NYSE:MRK) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
Express News | FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (Sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With Egfr Mutations
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
Merck & Co Unusual Options Activity For December 02
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $110
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December Starts With a Mixed Market | Live Stock